Press Releases Any 2022 (-) 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2021 December 17, 2021 argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis November 10, 2021 argenx to Present at Upcoming Investor Conferences October 28, 2021 argenx Reports Third Quarter 2021 Financial Results and Provides Business Update October 21, 2021 argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021 October 8, 2021 argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings September 2, 2021 argenx to Present at Upcoming Investor Conferences August 25, 2021 argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis August 4, 2021 argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference July 29, 2021 argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update July 22, 2021 argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 July 14, 2021 argenx to Host Virtual R&D Day on July 20, 2021 June 16, 2021 argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology Pagination Current page 1 Page 2 Page 3 Next page Next › Last page Last »
